Accent targeting RNA-modifying proteins with $40M series A

RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital.

Accent’s preclinical assets are designed to treat cancer by targeting enzymes that modify RNA. The company is developing small molecule inhibitors against four undisclosed enzymes that are implicated in both solid and hematological tumors (see BioCentury, May 18).